Navigation Links
Oncothyreon reports first quarter 2009 financial results
Date:5/14/2009

storical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding future expenses, clinical development activities and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com.

'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon regains compliance with NASDAQ listing requirements
2. Oncothyreon to present at Invest Northwest 2009
3. Oncothyreon reports full year and fourth quarter 2008 financial results
4. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
5. Oncothyreon to present at BIO CEO & Investor Conference 2009
6. Oncothyreon reports third quarter 2008 financial results
7. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
8. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
9. Oncothyreon to present at BIO Investor Forum 2008
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Oncothyreon announces prioritization plan for development programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... today that they have been acquired by Roche (SIX: ... a privately held company that provides a big data ... sequencing (NGS) data for the academic and translational research ... Unit, and will continue to focus on development of ...
(Date:12/19/2014)... 2014 Research and Markets ( ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research ... a detailed assessment on technological advancements and market ... 1. The Smart Fabrics market is ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... , , , SOUTH SAN ... ) received, as previously disclosed on its Current Report on Form ... 2009 and in its press release on April 1, 2009, a ... 2009, informing Anesiva that it was not in compliance with Marketplace ...
... , , , ... NBIX ) announced today that the Company will report its ... July 29, 2009. Neurocrine will then host a live ... Company update Thursday morning, July 30, 2009 at 8:30 a.m. Eastern Daylight ...
... , DALLAS, July 23 AC ... S PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) , ... data from a post approval study of MuGard in head and neck cancer patients ... multi-center study expected to enroll a total of 280 patients, patients are provided with ...
Cached Biology Technology:Anesiva Receives NASDAQ Delisting Staff Determination Letter 2Anesiva Receives NASDAQ Delisting Staff Determination Letter 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 2MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Investigators at Nationwide Children,s Hospital may have discovered a ... spinal muscular atrophy (SMA) symptoms and why breathing treatments ... Human Molecular Genetics .* SMA is a ... leading to death. Respiratory support is one of the ...
... University scientist Chittaranjan Kole was awarded the Outstanding Crop ... He was one of three scientists to receive the ... the field of crop science. He also chaired a ... this month, "Genomics and Breeding of Climate Resilient ...
... frontal lobes are the largest part of the human ... most during human evolution. Damage to the frontal lobeswhich ... in profound impairments in higher-level reasoning and decision making. ... the frontal lobes do, neuroscientists at the California Institute ...
Cached Biology News:Low oxygen levels may decrease life-saving protein in spinal muscular atrophy 2Thinking and choosing in the brain 2Thinking and choosing in the brain 3
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
...
Vitellogenin (Japanese medaka) Standard...
... SAGE (serial analysis of gene ... expression analysis. Expression profiles generated ... to detect low-abundance transcripts making ... genes. The I-SAGE Kit is ...
Biology Products: